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DOI: 10.1039/c0md00274gIn this study, folic acid-protected gold nanoparticles (FA-GNPs) were fabricated by one-step reduction
of HAuCl4 by folic acid under microwave irradiation. FA-GNPs were successfully used to target and
detect human cervical carcinoma cells.Introduction
Folic acid (FA) conjugated with gold nanoparticles (GNPs) has
been successfully used in targeting and imaging cancer cells,
because folate receptors are up-regulated on a variety of human
cancers.1,2 Numerous attempts using polymers to develop
biodegradable hydrophilic folate–nanoparticle conjugate have
been reported.3,4 In our previous study, FA was coupled on the
GNP surface through glutathione, and the targeting of FA-
GSH-GNPs in human cervical carcinoma cells (HeLa cells) was
confirmed.5 The limitations of these methods are that a linkage
mediator is required to connect GNPs with FA, which makes the
procedure complicated and time-consuming. To overcome these
problems, we developed a facile one-step method to fabricate
FA-GNPs under microwave irradiation.
There are a large number of ways to synthesize GNPs. The
reducing reagents could be either inorganic, such as sodium/
potassium borohydrate, hydrazine and salts of tartrate, or
organic, such as sodium citrate and ascorbic acid.6 Recently,
more and more biomolecules have been used as reducing agents
to prepare GNPs, including amino acids, chitosan, glucose,
peptides, nucleotides and vitamin B2. These molecules can create
stable GNPs of consistent sizes in a water-based environment.6–11
Moreover, biomolecule-functionalized GNPs are non-toxic and
can be easily adapted for biological applications. FA is
comprised of para-aminobenzoic acid linked at one end to
a pteridine ring and at the other end to glutamic acid (Scheme 1).
The 2-amino group (–NH2) and 4-hydroxyl group (–OH) on the
pteridine ring possibly reduce the gold ion to the gold particle.
And FA adsorbed on the surface of the GNPs provides colloidal
stability owing to its negative charge. So in our reaction, FA acts
as both the reducing and stabilizing agent.Department of Biomaterials, College of Materials, Research Center of
Biomedical Engineering, Xiamen University, Xiamen, 361005, People’s
Republic of China. E-mail: sunliping@xmu.edu.cn; Fax: +86 (0)592-
2185299; Tel: +86 (0)592-2183181
† Electronic supplementary information (ESI) available: Experimental
section and characterization details. See DOI: 10.1039/c0md00274g
This journal is ª The Royal Society of Chemistry 2011Microwave synthesis is an invaluable tool for medicinal
chemistry and drug discovery applications since it is quite fast,
simple and very energy efficient compared to conventional
thermal convection.12,13 Many successful applications of micro-
wave heating have been reported to yield platinum, silver, gold
and other nanoparticles in solution.14–18 In this paper, we report
a microwave irradiation-based strategy for the preparation of
gold nanoparticles by direct microwave irradiation of a
FA/HAuCl4 aqueous solution without the additional step of
introducing other reducing agents and protective agents.
Significantly, these FA-capped GNPs have precisely controlled
sizes and are highly stable. And based on a simple spectroscopic
method, FA-GNPs were successfully used to detect HeLa cells
with a detection limit of 750 cells.Results and discussion
For the synthesis of gold nanoparticles, FA solution (0.2 mL, 1.0
mM) was added to HAuCl4 (5 mL, 0.8 mM) solution under
magnetic stirring. Due to the poor solubility of FA in acidic
HAuCl4 solution, some precipitate appeared. For this reason, 1
mol L1 NaOH was subsequently added to obtain a clear orange
solution (pH 10.60). The solution was stirred for 30 min and
immediately placed in a sealed vessel and reacted in a microwave
reactor. The reactions were run for 2 h at 100 C. The resulting
solution appeared wine red, indicating the formation of gold
nanoparticles. This was further confirmed by UV-vis spectros-
copy (Fig. 1A), which showed a surface plasmon band aroundScheme 1 The chemical structure of folic acid.
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View Article Online529 nm. The as-prepared FA functionalized GNPs (FA-GNPs)
were characterized by high-contrast transmission electron
microscopy (TEM), Fourier transform infrared spectroscopy
(FTIR), X-ray photoelectron spectroscopy (XPS), and X-ray
diffraction (XRD).
TEM images of the FA-GNPs displayed well-dispersed
spherical nanoparticles with a size range of 15  5 nm (Fig. 1B).
The shadow around the spherical gold core could be free folic
acid wrapped around the individual nanoparticles. UV-vis
spectra showed that the FA-GNPs were stable in PBS buffer up
to a concentration of 0.6 mM (Fig. S1†). The comparison of the
FTIR spectra of the FA-GNPs and FA is shown in Fig. 2. The
characteristic bands of folic acid at 1699 (amide I) and 1604
(amide II) are also shown in the FA-GNPs conjugate, indicating
successful tailoring of the nanoparticle surface with FA.19 The
–NH2 double bands of the pteridine ring (3530, 3415 cm
1) dis-
appeared in the FA-GNPs conjugate. This may provide evidence
that the –NH2 group has been conjugated to the GNPs by
forming a N–Au bond. The binding of FA to the GNPs is also
demonstrated by the presence of C, N, O on the surface of gold
nanoparticles (XPS data, Fig. S1†). The binding energy of Au 4f
5/2 and Au 4f 7/2 appears at 87.5 eV and 84.0 eV, which is
consistent with the emission of 4f photoelectrons from Au0,
thereby suggesting the successful formation of GNPs.10 XRD
results revealed the crystalline nature (face-centered cubic
structure) of the FA-GNPs (Fig. S3†). The cytotoxicity of theFig. 2 FTIR spectra of (a) FA-GNPs, (b) pure folic acid.
1080 | Med. Chem. Commun., 2011, 2, 1079–1082FA-GNPs was evaluated by aWST-1 assay after incubation with
FA-GNPs for 12, 24 and 36 h, respectively (Fig. S4†). HeLa cell
viability remained over 80% after treatment with FA-GNPs for
36 h, implying that FA-GNPs are biocompatible at a concen-
tration of up to 100 mg mL1.
In order to obtain a quantitative measurement of GNPs in the
cells, inductively coupled plasma mass spectroscopy (ICP-MS)
was used to quantify the content of Au in each cell sample. HeLa
cells, a human cervical carcinoma cell line that is known to
overexpress folate receptors (FAR), were chosen for these
experiments. To study the relationship between intracellular
uptake and incubation time, cells were cultured for intervals of 1,
2, 3, 4, and 5 h. As shown in Fig. 3A, the amount of FA-GNPs or
13 nm citrate-capped GNPs in HeLa cells increases gradually
with incubation time. The intracellular uptake of FA-GNPs is
faster than that of GNPs. The uptake rate of the FA-GNPs
reaches a maximum level at an incubation time of 3 h, while that
of the GNPs reaches a plateau at 5 h. To confirm the receptor-
mediated uptake, competition experiments were conducted.
Fig. 3B shows intracellular uptake of nanoparticles after 3 h co-
incubation of FA-GNPs or GNPs with HeLa cells. Cells were
first saturated with free FA. The cellular uptake of FA-GNPs
gradually decreases with increasing FA concentration, because
the binding of FA to folate receptors in HeLa cells competitively
prevents FA-GNPs binding to FAR. In contrast, no obvious
changes of the cellular uptake of GNPs are found. These results
clearly demonstrate the preferential accumulation of FA-GNPs
in HeLa cells, and show that folate-receptor-targeting conjuga-
tion promoted this tumor preferential accumulation of particles.
Scheme 2 illustrates that the receptor-mediated endocytosis
enhances the internalization of FA-GNPs by target cells
compared with citrate-capped GNPs (Scheme 2A, 2B), and folic
acid competitively inhibits their binding to the folate receptor
and reduces the uptake by cancer cells (Scheme 2C).
Based on a simple spectroscopic method, FA-GNPs were
successfully used to detect HeLa cells. FA-GNPs bound to
cancer cells can be easily deposited together with the cells at low-
speed centrifugation (1000 rpm), leading to a decrease in
absorbance of the supernatant at 529 nm. DA was calculated
according to the following formula: DA ¼ A0  A1 (A0 ¼
Absorbance of blank, A1 ¼ Absorbance of supernatant). Two
cell lines were selected in this study, FAR-abundant HeLa cells
(target cell line) and FAR-deficient fibroblasts (FB cells, controlThis journal is ª The Royal Society of Chemistry 2011


































View Article Onlinecell line). In Fig. 4A, four samples are as follows: FA-GNPs,
FA-GNPs in PBS, FA-GNPs with 30 000 FB cells in PBS, and
FA-GNPs with 30 000 HeLa cells in PBS. After centrifugation,
the absorbance of FA-GNPs with HeLa cells is significantly
lower than that of FA-GNPs with FB cells. These results indicate
that the FA-GNPs are binding selectively to the target cells and
that the assembly of the FA-GNPs around the target cells causes
a decrease in the absorption of the supernatant. UV-vis spectra
for different amounts of target and control cells are shown in
Fig. 4B and 4C, respectively. There is little change in the FA-
GNP absorption spectra of the FB cell samples regardless of the
amount of cells present. It is obvious that the higher the HeLa
cell concentration, the higher the DA is (Fig. 4D), suggesting that
more nanoparticles are being deposited at 1000 rpm by targeting
HeLa cells. DA of the control cells (FB) has little change inScheme 2 Schematic illustration of the intracel
This journal is ª The Royal Society of Chemistry 2011comparison to the blank because FA-GNPs cannot bind to
fibroblast cells owing to the lack of folate receptors. The nano-
particles still remain in the supernatant after low-speed centri-
fugation. In the range of 100 to 105 cells mL1, HeLa cells and FB
can be distinguished clearly by a significant difference inDA of all
groups (P < 0.05, Student’s t-test for paired data). A detection
limit of 100 cells mL1 was obtained. This assay showed a linear
correlation between DA and the amount of HeLa cells ranging
from 102 to 105 cells mL1 (DA ¼ 0.9168 + 0.0450 C, correlation
coefficient of 0.9940). Based on these results, the assay has
demonstrated excellent sensitivity and selectivity. Compared
with our previous synthetic process of FA-GSH-GNPs,5 the
preparation of FA-GNPs is more convenient, requiring only
a one-step reaction. FA acts as both the reductant of HAuCl4
and the target molecule for folate receptors on the cancer cells.lular uptake of nanoparticles by HeLa cells.
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Fig. 4 A: UV-vis spectra of FA-GNPs, FA-GNPs in PBS, supernatant of FA-GNPs with 30 000 HeLa cells in PBS, FA-GNPs with 30 000 FB cells in
PBS. B: Spectra for different amounts of HeLa cells. C: Spectra for different amounts of FB cells. D: DA of the target HeLa cells (black line) and


































View Article OnlineThe sensitivity of FA-GNPs for cancer cell detection remains the
same as that of FA-GSH-GNPs (100 cells mL1). In addition, the
size of FA-GNPs can be modulated by using a different mole
ratio of [FA]/[HAuCl4].
Conclusions
In summary, a straightforward and rapid process has been
developed to synthesise folic acid-conjugated gold nanoparticles.
The ICP-MS analyses showed that these nanoparticles could
successfully target tumor cells overexpressing the folate recep-
tors. FA-GNPs have been demonstrated for the sensitive and
selective detection of human HeLa cells through utilizing the
unique spectral properties of gold nanoparticles and the excellent
selectivity of folic acid. The results collected in this study indicate
that FA-GNPs may be used as efficient materials for biomedical
applications such as cancer diagnosis and therapy.
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